Blogs

29
Mar 2022

E-Scan MicroCurrent Technology - Quality Assurance Solution for Parenteral Product Packaging

E-Scan MicroCurrent Technology - Quality Assurance Solution for Parenteral Product Packaging

As technological advancements lead to an ever-increasing world of routes of administration for new and existing drugs, packaging decisions for such options have become more challenging. There are multiple options for drug delivery container formats, and each should be continuously reviewed with reference to compliance and accuracy of delivery. Packaging is a critical point of concern whenever a new drug product is introduced into the market. When it comes to parenterals, there has been a dramatic increase in these packaging formats over the past 10 years. Apart from typical formats of vial and syringes, dual-chamber devices, cartridges and electronically enabled devices have been introduced, all which demand high levels of packaging accuracy. So how do we ensure the ability of the packages to maintain sterility of the drug? Quality assurance with the proper Container Closure Integrity Test (CCIT) method is critical.

CCI Testing using E-Scan 655 MicroCurrent HVLD

The E-Scan 655 technology utilizes the MicroCurrent conductivity test method to non-destructive evaluate container closure integrity. MicroCurrent technology exposes the package and product to lower voltage than other conductivity based solutions. This unique technology requires no sample preparation and is a non-contact and non-invasive test method. What makes E-Scan 655 technology unique is its ability to test a wide range of liquid-based products including low conductivity sterile water for injection (WFI) and proteinaceous products with suspensions. The system also features a fast test cycle and is simple to operate. Additional benefits include quick product changeover and an easy recipe set up to accommodate a wide range of products and applications. The offline E-Scan 655 method can be migrated from the laboratory to automated 100% inline testing applications at high production speeds.

Testing Procedure

Using a set of electrode probes, E-Scan system tests a non-conductive container that is sealed. The container material can vary from glass, plastic, or poly laminate. The container or package must contain liquid (minimum fill 30%). In case of any defect including pinhole or crack, there will be a resistance differential and change in current flow indicating a breach in the container. The approximate defect location can be identified.

Benefits of MicroCurrent HVLD technology:

  • Non-destructive, non-invasive, no sample preparation
  • High level of repeatability and accuracy
  • Effective across all parenteral products, including extremely low conductivity liquids (WFI)
  • Lower voltage exposure produces no ozone, eliminating risk to the product and environment
  • Listed in USP Chapter <1207> as recommended method for parenteral liquid package integrity testing
  • Robust method and approximate 3x Signal-Noise-Ratio for a wide range of product classes and package formats
  • Simplifies the inspection and validation process
Readmore...
E-Scan, microCurrent hvld, parenteral product packaging, ccit, container closure integrity
107
21
Dec 2021

Why Manufacturers Rely on High Voltage Leak Detection Technology to Ensure Pharmaceutical Package Integrity

Why Manufacturers Rely on High Voltage Leak Detection Technology to Ensure Pharmaceutical Package Integrity

Packaging is an essential part of the pharmaceutical industry, given the sensitive nature of the contents. High-risk medications and lifesaving drugs need utmost care and protection until they reach the patient. As such, stringent industry standards apply to pharmaceutical packaging. Manufacturers give high priority to safety and quality while selecting packaging materials for a drug or healthcare product. The packaging should be able to act as a barrier against external contamination and chemical reactions. Exposure to reactive gases can alter the physical, chemical and biological attributes of the products. This makes Container Closure Integrity Testing of pharmaceutical packaging a regulatory requirement.

Role of MicroCurrent HVLD in ensuring pharmaceutical package integrity

Often referred to as the conductivity and capacitance test, High Voltage Leak Detection (HVLD) is a test method found to be highly effective in detecting the presence and location of leaks in a wide range of pharmaceutical and parenteral applications. It can be used for leak testing in nonporous, rigid or flexible packages, as well as packages containing liquid or semi-liquid products. High Voltage Leak Detection test is conducted using electrical conductivity and resistance principle. This method operates by passing high voltage micro current signals through sample packages. Under the presence of a leak, the electrical resistance of the sample declines, causing an increase in current. Compared to other leak detection methods that rely on flow of gas or liquid, HVLD technology relies on “flow” of current. This reduces challenges with defect clogging compared to flow-based analysis.

The latest evolution of HVLD, PTI’s patent pending MicroCurrent technology, aims to achieve a high level of CCI assurance across the entire range of pharmaceutical products. The MicroCurrent HVLD reduces voltage exposure to the product to less than 5% of the voltage exposure experienced when testing with comparable HVLD solutions. Reducing exposure voltage not only reduces any risk that the voltage poses to the product, but also greatly reduces the production of Ozone during operation when compared with traditional HVLD solutions. Ozone in the headspace of a container can be detrimental to the product, and in the operating environment can affect respiratory health.

Benefits:

  • Non-destructive Container Closure Integrity Test (CCIT)
  • Requires no sample preparation
  • Capability to test multiple packages in a single test cycle
  • Identifies which package is defective
  • Simplifies the inspection and validation process
  • Supports sustainable packaging initiatives
  • ASTM test method and FDA standard
  • Cost effective with rapid return on investment
  • Readmore...
    hvld, package integrity testing, ccit, container closure integrity, microcurrent hvld
    185
    13
    Aug 2021

    VeriPac LPX for Automated Inspection of Parenteral Products

    VeriPac LPX for Automated Inspection of Parenteral Products

    Parenteral product package systems are expected to provide barriers against drug contamination and ensure stability and sterility throughout the entire shelf life. Any defect in packaging can cause microbial contamination, exposure to gases and water vapor, resulting in product deterioration. Furthermore, the industry has seen a spike in demand for combination products and patient-centered drug delivery systems, that present a high level of technical risk for maintaining container closure integrity (CCI). Therefore, container closure integrity testing is an important stage in the sterile drug product lifecycle.

    Automated package inspection with VeriPac LPX

    As the pharmaceutical industry continues to grow, manufacturers require capable, consistent automated solutions for container closure integrity testing. Automated inspection systems improve package reliability, reduce chances of product recalls and packaging failure.

    PTI's VeriPac LPX series are a line of fully automated package quality inspection systems for 100% inline testing. The LPX enables enhanced automated testing that provides a high level of confidence in packaging line performance. Veripac LPX is a practical and reliable solution for the problems associated with performing infrequent testing as well as for recognizing and correcting process-related quality issues.

    Sensitivity and reliability go hand in hand with CCI testing. The VeriPac LPX 430.8S is the next generation automated inspection system for container closure integrity testing of parenteral products. Automated for 100% testing or batch release, the VeriPac PLX 430.8S is an eight-station dual chamber design, with robotic testing platform for pre-filled syringes and vials, products filled with lyophilized product, small molecule liquids and Water for Injection (WFI).

    The VeriPac LPX features a dynamic robotic design, tailored to fit varied production requirements. LPX Series are scalable, modular solutions to meet production line demands. This adaptable platform provides reliable automated handling of a variety of packaging formats. Applications for LPX automation range from flexible packaging to rigid containers, and parenteral products. Additionally, VeriPac LPX allows easy changeover for testing different size packages on the same system.

    Benefits of VeriPac LPX test systems

    • Automated testing enables the highest level of container quality assurance
    • Self-teach software
    • Non-drift transducers for consistent leak detection
    • Low false rejects
    • Operator friendly
    • Reject statistics & test result trends
    • 24/7 operation
    • Increased productivity
    • Reduced downtime
    • Low maintenance
    Readmore...
    veripac LPX, parenteral product leak testing, container closure integrity, ccit, automated inspection systems
    348
    30
    Apr 2021

    Understanding PTI’s MicroCurrent HVLD Technology

    Understanding PTI’s MicroCurrent HVLD Technology

    Container closure integrity may be understood as the ability of container closure systems to maintain a sterile barrier against possible contaminants that can deteriorate the quality of the final product. Even a microscopic leak or breach of the sterile barrier can cause external contaminants to enter the product and compromise its healing properties. Parenteral products are at the highest risk of all package formats. Vials, ampoules and prefilled syringes have the highest potential for microbial growth, and the risk to the end patient amplifies the focus needed on CCI for these applications. Although dye ingress and microbial ingress are common leak testing methods, they are proven to provide subjective results that lack accuracy. Hence regulatory bodies have instructed a shift towards more deterministic test methodologies that can be controlled, calibrated and provide a definitive determination of CCI.

    High Voltage Leak Detection (HVLD) is an effective Container closure integrity technique for non-destructive package inspection of non-porous pharmaceutical and parenteral products. This technology operates on the simple property of electrical current. The latest evolution of HVLD, PTI’s patented MicroCurrent HVLD technology , aims to achieve a high level of CCI assurance across the entire range of parenteral products. It can precisely detect any leak in a wide range of liquid- filled products including extremely low conductivity sterile water for injection (WFI) and proteinaceous products with suspensions. The MicroCurrent HVLD reduces voltage exposure to the product to less than 5% of the voltage exposure experienced when testing with comparable HVLD solutions. Reducing exposure voltage not only reduces any risk that the voltage poses to the product, but also greatly reduces the production of Ozone during operation when compared with traditional HVLD solutions.

    How does MicroCurrent HVLD technology work?

    Under this method, the container is scanned by the high voltage probes. High voltage is applied to one side of the container and a ground probe on the opposing side. If the package has no leak, the two container walls (high voltage side and ground side) provide full electrical resistance and no significant current is measured passing through the vial. If there is a micro-leak or crack in one of the container walls, the break-down resistance is reached and the current passes through. HVLD is the only leak detection technology that does not require mass to pass through a defect site, requiring only the passage of electricity through a crack. This characteristic makes HVLD sensitive to leaks in which most leak test solutions cannot identify. Applications of High Voltage Leak Detection Technology include testing of the following package formats:

    • Pre-filled syringes
    • Ampoules
    • Drug product cartridges
    • Liquid filled vials

    Benefits of MicroCurrent HVLD:

    • Deterministic, non-destructive, non-invasive
    • High level of repeatability and accuracy
    • Ideal package integrity solution for parenteral products
    • Low voltage exposure to the product and environment
    • Offline and 100% online inspection at high production speeds
    • Referenced in USP 1207 guideline
    Readmore...
    high voltage leak detection technology, container closure integrity, container closure integrity testing, USP 1207, microcurrent HVLD, HVLD
    555
    15
    Apr 2021

    Evaluating Container Closure Integrity of High-Risk Pharmaceuticals

    Evaluating Container Closure Integrity of High-Risk Pharmaceuticals

    The pharmaceutical industry is crucial to the health care system as they assure treatments that were unimaginable a few years ago. As the industry grows in importance, the techniques of primary packaging for pharmaceutical products, especially high-risk medicines have taken on new prominence.

    Since many high-risk pharmaceutical products are filled and sealed in combination devices, it’s critical for manufacturers to ensure that the components function well together. Hence, design and distribution considerations are critical to both the drug and the container. Manufacturing inconsistencies and tolerance differences in packages containing multiple components are primary contributors to distribution issues. Often, such inconsistencies result in container closure failure, causing serious implications down the supply chain. For instance, glass vials and pre-filled syringes may not seal properly at critical fill-finish closure points. Such a failure can cause oxygen or other environmental contaminants to enter the product and compromise the efficacy of the drug in the barrel. At this point, it is critical to use the most precise leak testing method possible.

    Why Container Closure Integrity testing is important?

    As per the FDA- Food and Drug Administration, A container and closure system refers to "the entirety of packaging components that together contain and protect the product". In simple words, Container Closure Integrity testing can be understood as a leak detection test. CCI solutions include non-destructive package inspection technologies to ensure product sterility throughout the product’s lifecycle. CCIT plays a vital role in ensuring that the products are free from any possible contamination. Conventionally, probabilistic test methods like bubble tests, dye ingress and microbial challenge were extensively used in pharmaceutical package testing. Since it was found that such test results lacked accuracy and reliability, the United States Pharmacopeia (USP) released guidance in 2016 stating that deterministic methods are preferred over probabilistic test methods. With this new USP <1207> chapter guidance, manufacturers today rely on non-destructive alternatives like Vacuum Decay technology and Micro Current HVLD technology that ensure highly sensitive package integrity solutions.

    1. Vacuum Decay technology: Vacuum Decay technology is a non-destructive container closure integrity solution capable of detecting leaks in nonporous, rigid or flexible packages. Vacuum Decay leak testing is conducted by placing a sample package in a well-fitting evacuation chamber, which is provided with an external vacuum source. The vacuum levels as well as the change in vacuum over a fixed test time are closely observed using single or dual vacuum transducer technology. Changes in vacuum level beyond a predetermined pass/fail limit indicate defects within the package. VeriPac Vacuum Decay series can non-destructively test packaging down to sub-micron leak rates - making it an excellent alternative to destructive testing methods.

    PTI’s VeriPac 465, the latest addition to the vacuum decay series is a robust and reliable solution for testing pharmaceutical containers and parenteral products, achieving highly sensitive sub-micron leak detection. The VeriPac 465 is the most sensitive vacuum based technology on the market to-date.

    Benefits of Vacuum Decay Technology:

    • Non-destructive, non-subjective, no sample preparation
    • Deterministic test method that provides quantitative results
    • Multiple package testing in a single test cycle
    • Economical with rapid return on investment
    • ASTM Test Method, FDA standard and USP 1207 Guidance

    2. Microcurrent HVLD technology: Microcurrent HVLD is a unique High Voltage Leak Detection technology, highly effective across all liquid filled parenteral products. Its applications include liquid-based products ranging from extremely low conductivity sterile water for injection (WFI) to large molecule-based proteinaceous products with suspensions. Its ability to detect small pinholes, micro cracks and seal defects makes it an ideal choice for testing high risk pharmaceutical and parenteral products.

    Benefits of PTI’s MicroCurrent HVLD technology:

    • Non-destructive, non-invasive, no sample preparation
    • Highly effective across all parenteral products, including extremely low conductivity liquids (WFI)
    • Ensure higher levels of accuracy and reliability in test results
    • Simplifies the inspection and validation process
    • Offline and 100% online inspection
    • Referenced in USP 1207 Guidelines
    Readmore...
    CCIT, container closure integrity testing, container closure integrity, vacuum decay technology, high risk pharmaceuticals, hvld
    987
    19
    Mar 2021

    Why is MicroCurrent HVLD Technology a Preferred CCI Technique for Ensuring Integrity of Biologic Products

    Why is MicroCurrent HVLD Technology a Preferred CCI Technique for Ensuring Integrity of Biologic Products

    Often described as the driving force of pharmaceutical industry, biologic drugs have the ability to address chronic diseases, unmet medical needs and comprise of more than half of the drugs in development. These are generally large complex molecules, derived from human, animal, or microorganisms through biotechnology. Examples include blood components, cells, vaccines, tissues, and recombinant proteins. The ability of biological drugs to treat life threatening diseases coupled with aging population has lead to tremendous growth in the global biological drugs market. However, the rapid growth of biological products has also increased packaging challenges to deliver safe and effective products.

    Drug contamination is a serious concern in any medical industry; however, for biologics, it amplifies several folds because they are used to treat serious illnesses and chronic conditions. Contamination has a direct impact on product stability resulting in reduced shelf life and efficacy. Along with maintaining an acceptable shelf-life, there are other challenges too. Another important factor that can affect the quality of a drug is environmental conditions. For example, if a product is exposed to extreme temperature during transit, the product quality may be compromised. A biologic can also lose its stability if it’s unable to withstand variations in light and chemicals that it might encounter. Therefore, in order to cover packaging challenges associated with biological products, ensuring its container closure integrity is crucial.

    Ensuring package integrity with PTI’s MicroCurrent HVLD technology

    PTI’s MicroCurrent HVLD technology is a non-destructive, non-invasive container closure integrity test method that is found to be highly effective across applications such as pre-filled syringes, vials, cartridges, ampoules, BFS, bottles and pouches. This technique can precisely detect any leak in a wide range of liquid-filled products including extremely low conductivity sterile water for injection (WFI) and proteinaceous products with suspensions. Under this method, the sealed container is scanned using electrode probes to detect the presence of any leak. Defects in the container as well as its approximate location can be identified by analyzing a change in the current flow. MicroCurrent HVLD technology utilizes about 50% less voltage and exposes the product and environment to less than 5% of the voltage when compared to conventional HVLD solutions. It is one of the most effective CCI technologies for all parenteral and biologic products.

    Benefits of PTI’s MicroCurrent HVLD technology

    • Non-destructive, non-invasive, no sample preparation
    • Highly effective across all parenteral products, including extremely low conductivity liquids (WFI)
    • Ensure higher levels of accuracy and reliability in results
    • Offline and 100% online inspection at high production speeds
    • Simplifies the inspection and validation process
    • Referenced in USP 1207 Guideline
    Readmore...
    Microcurrent HVLD, CCI, container closure integrity, container closure integrity testing, Integrity of biologic products
    724
    11
    Dec 2020

    What are the Different Seal Quality Inspection Techniques Offered by PTI?

    What are the different seal quality inspection techniques offered by PTI

    Seal integrity plays a vital role in ensuring the quality of packaging products. Even a minute defect in the seal can initiate a leak, which can compromise the quality of the product and directly affect its shelf life. It can also result in huge financial losses to the manufacturer. That being said, manufacturers give considerable importance to conducting appropriate seal integrity tests to ensure package integrity at every stage of its lifecycle.

    Seal integrity testing methods can be classified into two- Destructive testing methods and Non-Destructive testing methods. Since under Destructive methods, the packages may get destroyed, its popularity has steadily declined over the past few decades due to this waste and high cost. “There is a huge shift in the industry towards deterministic and quantitative test methods,” says Oliver Stauffer, Chief Executive Officer at PTI - Packaging Technologies & Inspection. “This includes vacuum decay and airborne ultrasound for medical device applications. The industry is currently moving away from dye ingress and manual visual inspection because there are so many blind spots in applying them and there’s a huge false sense of assurance.”

    Seal quality inspection techniques offered by PTI:

    Vacuum Decay technology is a non-destructive Container Closure Integrity test method, used for seal quality inspection in nonporous, rigid or flexible packages. With the ability to detect leaks down to the sub-micron level, , Vacuum Decay technology is identified as one of the most practical vacuum-based leak detection methods. Its ability to provide quantitative, reliable and repetitive test results make it ideal solution for seal quality inspection in Pharmaceutical, Medical Device and Food and Nutrition industries.

    Under this method, the sample packages are first placed in a close fitting evacuation test chamber that contains an external vacuum source. The vacuum levels and changes in vacuum over a pre-determined time are closely monitored. The single or dual vacuum transducer technology is used to monitor the test chamber for both the level of vacuum as well as the change in vacuum over a predetermined test time. The changes in the absolute and differential vacuum indicate the presence of leaks and defects within the package.Over the past few years, Vacuum Decay technology has seen great advancements in the form of PTI’s PERMA-VAC technology and VeriPac FLEX Series.

    The next generation PERMA-VAC technology is a single or dual vacuum transducer technology that has made the VeriPac line of test systems the most sensitive vacuum-based leak tests available in the market. It has higher test sensitivity for providing accurate and reliable results and can be applied to rigid and semi-flexible packages alike. PTI’s PERMA-VAC technology ensures the most stable test measurement ever achieved through vacuum decay.

    VeriPac FLEX series is an ideal package inspection solution for dry filled pouches and flexible packaging. To accommodate different package formats and test sensitivity requirements, VeriPac FLEX series is available in several configurations with multiple test chamber sizes.

     

    2.Airborne Ultrasound technology:

    Airborne Ultrasound technology is yet another seal quality inspection technique, which is capable of non-destructively conducting advanced seal quality inspection of pouches and flexible packaging. It is capable of accommodating multiple packaging materials like Tyvek, paper, foil, film, aluminum, plastic and poly and is also proven to provide deterministic, reliable and accurate test results.

    As the name suggests, this method utilizes ultrasound waves to detect defects in package seals. Ultrasound waves are passed through the material as the package seal moves along the sensor head. This causes reflections of sound waves. Such signal strength variations are closely monitored to identify defects if any. Its ability to evaluate seal quality even under conditions where the defect may not result in a leak, makes Airborne Ultrasound technology a practical choice for seal quality inspection across different industries.

    PTI’s Seal-Scan (Offline) and Seal-Sensor (Online) are the latest advancements to the ultrasound test series. Both these technologies make use of non-contact airborne ultrasonic testing technology and have been established as one of the most effective methods for inspection of flexible package seals. Airborne ultrasound is also an ASTM Test Method F3004 for seal quality inspection.

     

    Readmore...
    seal quality inspection, airborne ultrasound technology, vacuum decay technology, container closure integrity testing, ccit, container closure integrity
    537
    09
    Dec 2020

    Role of MicroCurrent HVLD Technology in Parenteral Product Container Closure Integrity (CCI) Testing

    Role of MicroCurrent HVLD Technology in parenteral product container closure integrity (CCI) testing

    Ensuring pharmaceutical package integrity has always been a priority for drug product manufacturers. However, over the past few decades, innovations in health care sector have also accelerated pharmaceutical package integrity challenges. Although testing package quality of all healthcare products is important, in the case of parenteral products it is amplified significantly. Parenteral products are defined as injectible products that can be either liquid or powders. Solutions can contain suspensions, emulsions and be proteinaceous in nature. ”. Since these drugs are directly administered into human bodies, ensuring complete integrity of such packages is crucial. Common packaging formats for parenteral products include Liquid-filled containers such as vials, ampoules, syringes, BFS and auto injectors; Lypholized (powder) products are often packaged in vials. Even a minute breach in the package can cause microbial contamination leading to product deterioration. Hence ensuring container closure integrity is a critical process in the life cycle of parenteral products.

    What is HVLD Methodology?

    High Voltage Leak Detection (HVLD)) is a non-destructive Container Closure Integrity technique used primarily to evaluate closure integrity of parenteral product packaging. HVLD technology makes use of quantitative electrical conductivity measurement principles. This method operates by passing high voltage micro current signals through sample packages. Under the presence of a leak, the electrical resistance of the sample declines, causing an increase in current. Applications of High Voltage Leak Detection Technology include testing of the following package formats:

    • Pre-filled Syringes
    • Ampoules
    • Drug Product Cartridges
    • Liquid Filled Vials
    • Blow-Fill-Seal (BFS) Container

    PTI’S MicroCurrent HVLD technology has revolutionized the conventional HVLD method. MicroCurrent HVLD is a non-destructive, non-invasive CCI technique that can be applied to a wide range of liquid filled products including low conductivity sterile water for injection (WFI) and highly proteinaceous drug products within suspensions. PTI’s E-scan HVLD, a highly sensitive CCI testing process uses electrode probes to scan sealed non-conductive containers. Under the presence of a leak, there will be a change in current flow indicating a defect in the container along with its approximate location. This unique technique uses about 50% less voltage and exposes the product and environment to less than 5% of the voltage. An important feature of E-scan HVLD is its ability to easily shift from the laboratory offline to 100% inline testing applications. With the capability to accommodate multiple packaging formats including glass, plastic or poly laminates, it is an ideal solution for parenteral package testing.

    Benefits of MicroCurrent HVLD:

    • Deterministic, non-destructive, non-invasive
    • High level of repeatability and accuracy
    • Ideal package integrity solution for parenteral products
    • Low voltage exposure to the product and environment
    • Offline and 100% online inspection at high production speeds
    Readmore...
    CCIT, container closure integrity, container closure integrity testing, parenteral product leak testing, MicroCurrent HVLD, CCI testing
    719
    04
    Sep 2020

    CCIT - A risk mitigation tool for parenteral products

    CCIT - A risk mitigation tool for parenteral products

    Today’s healthcare industry assures treatments that were unimaginable a few years ago. As pharmaceutical industry grows in importance, the techniques of primary packaging for healthcare products, especially parenteral products has taken on new prominence. Common parenteral packaging methods include Liquid-filled containers such as vials, ampoules, syringes, blow-fill-seals and auto-injectors and containers filled with lyophilized products. Since these drugs are directly administered into human bodies, high sensitivity integrity tests are required to ensure product quality throughout its shelf life. For reasons of safety, packaging material, integrity and design are regulated by Food And Drug Administration as strictly as the product itself.

    Container Closure Integrity Testing is a leak detection test conducted using a non-destructive packaging inspection system to protect the drug from any possible contamination. It is a crucial step in evaluating safety and integrity of the primary packaging so as to maintain a sterile barrier and to avoid leakage resulting in contamination of the drug. Packaging components like bottles, vials, syringes that are in direct contact with the product are called primary components while aluminum caps, cardboard boxes are secondary components as they are not in direct contact with the product. Proper packaging should be a priority for all drug products, but in case of parenteral products, these concerns amplifies several folds as they are directly injected. Hence initiating a proper container closure system is vital for product and consumer safety.

    Although Container Closure Integrity Testing can be performed in many different ways, it can be broadly classified into Probabilistic methods and Deterministic methods. Probabilistic test methods including Microbial Challenge by Immersion, Tracer Liquid Tests (e.g. Dye Ingress), Bubble Tests etc. are traditional test methods where result accuracy may be uncertain. On the other hand, Deterministic test methods like Electrical Conductivity and Capacitance Test (HVLD), Laser-based Gas Headspace Analysis, Mass Extraction, Pressure Decay provide quantitative results with high accuracy. The United States pharmacopeia released guidance in 2016 stating that deterministic methods are preferred over probabilistic test methods.Packaging Technologies And Inspection (PTI’s) Microcurrent HVLD technology and vacuum decay technology are the latest inventions in package integrity testing of parenteral products.

    1. Microcurrent HVLD Technology: Microcurrent HVLD is a unique High Voltage Leak Detection Technology, highly effective across all parenteral products. Its Applications include liquid-based products ranging from extremely low conductivity sterile water for injection (WFI) to proteinaceous products with suspensions. Its ability to detect small pinholes, micro cracks and seal defect detection down to single-digit microns makes it an ideal choice for testing parenteral products.

    2. VeriPac Vacuum Decay Technology: VeriPac Vacuum Decay Technology, based on the ASTM vacuum decay leak test method (F2338-09) and accredited by the FDA for package integrity testing, is a non-destructive inspection system, capable of defect detection down to 0.002 cc/min. This system is applicable for empty and pre-filled syringes, liquid-filled and lyophilized vials and other flexible and rigid liquid-filled packaging. Depending on the package type and leak test sensitivity needed, appropriate VeriPac model can be selected.

    PTI’s next generation PERMA- VAC technology addresses vacuum decay detection at the very core of physical test measurement by controlling the test system volume and maximizing the SNR between good and defective samples. This makes PERMA-VAC the most reliable vacuum-based leak test available in the market.
    Readmore...
    CCIT, parenteral product leak testing, container closure integrity testing, container closure integrity, package integrity testing, ccit pharmaceutical, hvld
    1491
    01
    Sep 2020

    Container Closure Integrity Testing (CCIT) - An Ideal Solution for the Pharmaceutical Industry

    Container closure integrity testing - An ideal solution for pharmaceutical industry

    The global pharmaceutical industry has seen tremendous growth over the last few decades. The complex nature of the industry coupled with frequent breakthroughs has made it a favorite subject of scrutiny. Since any defect in the packaging of drugs can have serious consequences, assuring the quality of the packaging is of prime interest for every manufacturer. Pharmaceutical products are expected to be free from microbial contamination and safe to use right from production throughout their shelf-life. The drug’s stability can be adversely affected through contamination in the form of oxygen, humidity or microbiological ingress. In order to prevent such risks, integrity tests with high sensitivity are required.

    Previously, only sterility testing was conducted on pharmaceutical packaging. However, when it was realized that sterility testing alone is not sufficient to hold the integrity of the medical products, the US FDA published Guidance for Industry for Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products. This emphasised the importance of verification of microbial barrier properties of a pharmaceutical product package (i.e., CCI). FDA defines Container Closure Integrity Testing (CCIT) “as the sum of packaging components that together contain and protect the dosage form”.

    Container Closure Integrity Testing is a method of leak detection using a non-destructive packaging inspection system to prevent possible contamination. Such a test is essential since any defect in the container can cause external particles to enter the product, thereby reducing its shelf life. Implementing right Container Closure System has been of prime importance for a manufacturer as it affects both the product and the patient. Hence, the relevance of CCI Testing in the pharmaceutical industry has steadily increased over the years. Contaminants that can enter a product include micro-organisms, reactive gases, and other substances. CCIT ensures product quality is maintained from the point of manufacture throughout its distribution and use. Container closure systems include primary packaging components and secondary packaging components. Components such as a glass vial or syringe, which come into direct contact with the product, are primary packaging components. On the other hand, components that are crucial to ensure correct package assembly, such as aluminum caps, over stoppers etc. are the secondary packaging components

    CCI Testing Methods

    Container closure integrity testing can be performed in many different ways. Each method has its own merits and demerits. A number of factors have to be considered while selecting appropriate testing methods. These factors include, but are not limited to; the reliability of the test method, material of the primary package and inline versus an offline testing requirement. CCI testing methods can also be selected depending on specific desired outcomes. Examples of desired outcome include: identifying the presence of leak paths, understanding leak path’s location, evaluating leak rate for the whole package, and measuring potential for microbial ingress. The United States pharmacopeia released guidance in 2016 stating that deterministic methods are preferred over probabilistic test method.

    1. Probabilistic methods: Here, the testing methods are more traditional, and the accuracy of the result is uncertain. The probabilistic methods include the following:
    • Microbial Challenge by Immersion
    • Tracer Liquid Tests (e.g. Dye Ingress)
    • Bubble Tests
    • Tracer Gas (Sniffer Mode)
    2. Deterministic methods: Such methods provide quantitative results with a higher level of accuracy. The chances of errors are also minimal. The deterministic methods include the following:
    • Electrical Conductivity and Capacitance Test (HVLD)
    • Laser-based Gas Headspace Analysis
    • Mass Extraction
    • Pressure Decay
    • Tracer Gas (vacuum mode)
    • Vacuum Decay
    Readmore...
    CCIT, container closure integrity, container closure integrity testing, pharmaceutical product leak testing, pharmaceutical package testing, package integrity testing
    1708

    Popular Blogs

    Tags

    Container Closure Integrity Testing (CCIT) - An Ideal Solution for the Pharmaceutical Industry

    Sep 01, 2020   |   1708

    Container Closure Integrity Testing is a method of leak detection using a non-destructive packaging inspection system to prevent possible contamination in pharmaceutical products.

    CCIT - A risk mitigation tool for parenteral products

    Sep 04, 2020   |   1491

    Container Closure Integrity Testing is a crucial step in evaluating the integrity of the primary parenteral packaging to avoid any leakage resulting in contamination of the drug.

    Automated CCI technologies- Revolutionizing medical device testing

    Sep 10, 2020   |   1071

    PTI revolutionized medical device package leakage testing with Automated CCI technologies across their different technology platforms

    Evaluating Container Closure Integrity of High-Risk Pharmaceuticals

    Apr 15, 2021   |   987

    High risk pharmaceuticals pose unique package integrity challenges for manufacturers. Even a minute leak in the container closure system can make way for contaminants to enter the products. Non-destructive container closure integrity tests like Vacuum Decay technology and Microcurrent HVLD technology offer highly sensitive leak detection with quantitative results.
    COPYRIGHT 2020, PTIUSA, ALL RIGHTS RESERVED PRIVACY AND COOKIES TERMS OF USE
    Popup